Stay updated with breaking news from Bacterial Core. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PREVENAR 20® offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of...
NEW YORK--(BUSINESS WIRE)--Mar 13, 2024--
NEW YORK, March 13, 2024--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20®, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age.
NEW YORK--(BUSINESS WIRE)--Mar 13, 2024--
The Centers for Disease Control said it has been monitoring a strain of strep throat known as Group A streptococcus in children.